Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Alvotech ( (ALVO) ).
On June 23, 2025, Alvotech announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of AVT06, a proposed biosimilar to Eylea® (aflibercept 2 mg). This recommendation marks a significant milestone for Alvotech, potentially enhancing its market position in Europe by increasing access to vital biologic treatments for eye disorders. The approval could impact stakeholders by expanding treatment options and potentially reducing costs associated with eye disorder treatments.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s score is primarily influenced by its financial performance, which indicates rapid growth but significant financial instability. The earnings call provided a positive outlook with raised guidance and strategic product launches. However, technical analysis shows bearish signals and valuation is moderately high, affecting the overall score.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide. The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products through a fully integrated approach. Alvotech’s pipeline includes biosimilar candidates for treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company has strategic partnerships to expand its reach across the United States, Europe, Asia, and other regions.
Average Trading Volume: 200,888
Technical Sentiment Signal: Sell
Current Market Cap: $2.82B
See more data about ALVO stock on TipRanks’ Stock Analysis page.